GlassScriptPhysician profile
Luis Alvarez
NPI 1487685368
$1,814,955.68
in general payments reported to CMS, 2019-2025
28 companies · $370K in 2025
The $370K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157K · 2020: $462K · 2021: $101K · 2022: $240K · 2023: $210K · 2024: $274K · 2025: $370K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $488K · Honoraria: $129K · Travel and Lodging: $121K · Consulting Fee: $85K · Food and Beverage: $24K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,200 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $487,776.61 |
| Honoraria | $128,548.29 |
| Travel and Lodging | $121,461.91 |
| Consulting Fee | $84,657.85 |
| Food and Beverage | $23,685.07 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,200.00 |
| Education | $139.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $719,290.90 | 2019-2024 | |
| Amgen INC. | $413,802.60 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $200,197.38 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $123,591.45 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $117,836.60 | 2024-2025 | Tarpeyo |
| Akebia Therapeutics INC | $75,396.70 | 2020-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $59,318.71 | 2019-2023 | Veltassa |
| Travere Therapeutics, INC. | $45,751.75 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $22,599.25 | 2023-2025 | |
| Kyowa Kirin, INC. | $18,756.77 | 2024-2025 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $9,363.45 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,012.78 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $2,185.40 | 2019-2025 | Jynarque |
| Genzyme Corporation | $1,841.00 | 2020 | |
| Lilly USA, LLC | $283.15 | 2024-2025 | Jardiance, Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $238.06 | 2019-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $232.42 | 2021-2024 | Benlysta, Jesduvroq |
| Edwards Lifesciences Corporation | $201.76 | 2023 | |
| Ardelyx, INC. | $184.92 | 2023-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $156.34 | 2022-2023 | Lupkynis |
| Bard Peripheral Vascular, INC. | $149.93 | 2019 | |
| Apellis Pharmaceuticals, INC. | $144.88 | 2025 | |
| Abiomed | $131.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.68 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $87.63 | 2022-2023 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $39.63 | 2025 | Acthar |
| Veloxis Pharmaceuticals, INC. | $19.60 | 2024 | Envarsus |
| Opko Pharmaceuticals, LLC | $18.83 | 2024 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.